IP Library Granted Patent US 7,459,481
Granted Patent B2
US 7,459,481 · App. 11/537,968 · Granted Dec 2, 2008

Stimulation of CPT-1 as a means to reduce weight

Assignee: The Johns Hopkins University School of Medicine Licensing And Technology Development
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,481
App. No.
11/537,968
Granted
Dec 2, 2008
Kind
B2
Abstract

This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

Claims (3)

1. A method of inducing weight loss comprising administering to a patient an effective amount of an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity in an amount that does not significantly inhibit FAS.

2. A method for stabilizing weight comprising chronic administration to a patient of an effective amount of an agent that stimulates CPT-1 activity in an amount that does not significantly inhibit FAS.

3. A method of screening for agents that induce weight loss, comprising determining whether a candidate weight loss agent stimulates CPT-1 activity in an amount that does not significantly inhibit FAS; and selecting an agent that stimulates CPT-1 activity in an amount that does not significantly inhibit FAS.

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 30, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044555/0964 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 20, 2015
From: D. E. DURAND FAMILY LIMITED PARTNERSHIP
To: FAS SECURED CREDITORS HOLDCO, LLC
Reel/Frame 036135/0568 →
FORECLOSURE - CONVEYANCE OF ENTIRE INTEREST OF ASSIGNOR. Recorded May 5, 2015
From: D. E. DURAND FAMILY LIMITED PARTNERSHIP, SECURED PARTY IN POSSESSION
To: D. E. DURAND FAMILY LIMITED PARTNERSHIP
Reel/Frame 035582/0453 →
SECURITY INTEREST Recorded Apr 29, 2015
From: FASGEN, INC.
To: D.E. DURAND FAMILY LIMITED PARTNERSHIP
Reel/Frame 035521/0202 →
Continuity (4)
Continuation 1091752500 · Aug 13, 2004
Continuation In Part 1050360500
Provisional Application 6035448000 · Feb 8, 2002
Related Publication 20070087037A1 · Apr 19, 2007